Science Sparks @ ACTREC
20th April 2026Publications
- 1. Thapa B, Fatima E, Gupta A, Shukla E, Verma D, Singh A, Parashar S, Sarita, Bawankule D, Khan F, Chanda D, Kode J, Negi A (2026). Benzofluorene derivative exhibits antiproliferative effect against leukemia by tubulin polymerisation inhibition. Sustainable Chemistry One World.
- 2. Suthahar T, Veerabhadrappa J, Munshi R, Anbu Raj E, Gota V, Ivaturi V, Mallayasamy S (2026). Factors influencing pharmacokinetics of 5-fluorouracil in cancer patients: a systematic review of population pharmacokinetic models. European Journal of Clinical Pharmacology. 82(5):126.
- 3. Mehrotra M, Shenoy P, Sakpal A, Chakraborty S, Ray P (2026). p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells. Biochemical and Biophysical Research Communications.
- 4. Zilli T, Zaorsky N, Maitre P, Desai N, Seibert T, Sun Y, Dess T, Tree A, Koontz B (2026). Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?International Journal of Radiation Oncology,Biology,Physics. 125 (1): 11-14.
Video of the Week
Precision Medicine for Cancer: The End of the Beginning
Upcoming Events
April 25, 2026
At ACTREC, Radiological Research Unit, Kharghar
May 28-29, 2026
At ACTREC, Radiological Research Unit, Kharghar
Do You Know?
In 2015, FDA approved talimogene laherparepvec (T-VEC) for the treatment of some patients with metastatic melanoma that cannot be surgically removed.
Cancer News
MedicalXpress, 16/04/2026
In total, 644 TNBC patients were enrolled in TROPION-Breast02 across multiple sites across the globe, including the United States, Canada, Europe, China, Korea, Japan and Singapore. Patients were randomly assigned to two treatment arms:...
Sciencedaily, 16/04/2026
Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells' readiness to attack tumors. Surprisingly, briefly suppressing the cells with a drug before use made them even more effective later...
News-Medical.Net, 14/04/2026
First, the potential of CTHRC1(+) CAFs as predictive markers of treatment response was studied across 17 cohorts comprising samples from nearly 3,000 patients. Next, tumor cell RNA was analysed at the single-cell level to identify the most promising cell populations. Finally, the proteins they expressed were...
© 2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)